 NEWTON, Mass., Dec. 7, 2020 PRNewswire -- Karyopharm Therapeutics Inc. Nasdaq:KPTI, a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that over twenty presentations related to XPOVIO selinexor, the Companys first-in-class, oral Selective... 